keyword
MENU ▼
Read by QxMD icon Read
search

Ceftolozane tazobactam

keyword
https://www.readbyqxmd.com/read/28096165/in-vitro-activity-of-ceftolozane-tazobactam-against-multidrug-resistant-non-fermenting-gram-negative-bacilli-isolated-from-patients-with-cystic-fibrosis
#1
Patrick Grohs, Gary Taieb, Philippe Morand, Iheb Kaibi, Isabelle Podglajen, Marie Lavollay, Jean-Luc Mainardi, Fabrice Compain
Ceftolozane-tazobactam was tested against 58 multidrug-resistant non-fermenting Gram-negative bacilli (35 Pseudomonas aeruginosa, 11 Achromobacter xylosoxydans and 12 Stenotrophomonas maltophilia) isolated from cystic fibrosis patients and compared to ceftolozane alone, ceftazidime, meropenem and piperacillin-tazobactam. Ceftolozane-tazobactam was the most active agent against P. aeruginosa but was inactive against A. xylosoxydans and S. maltophilia In time-kill experiments ceftolozane-tazobactam had complete bactericidal activity against 2/6 (33%) clinical isolates...
January 17, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28013453/pk-pd-target-attainment-with-ceftolozane-tazobactam-using-monte-carlo-simulation-in-patients-with-various-degrees-of-renal-function-including-augmented-renal-clearance-and-end-stage-renal-disease
#2
Alan J Xiao, Luzelena Caro, Myra W Popejoy, Jennifer A Huntington, Ravina Kullar
INTRODUCTION: Ceftolozane/tazobactam is an antibacterial agent with potent in vitro activity against Gram-negative pathogens, including many extended-spectrum β-lactamase-producing Enterobacteriaceae and drug-resistant Pseudomonas aeruginosa. Because ceftolozane/tazobactam is primarily excreted renally, appropriate dose adjustments are needed for patients with renal impairment. Monte Carlo simulations were used to determine the probability of pharmacokinetic/pharmacodynamic target attainment for patients with varying degrees of renal function, including augmented renal clearance (ARC) and end-stage renal disease (ESRD) with hemodialysis...
December 24, 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28007721/physical-compatibility-of-ceftolozane-tazobactam-with-selected-i-v-drugs-during-simulated-y-site-administration
#3
Abrar K Thabit, Yukihiro Hamada, David P Nicolau
PURPOSE: Results of a study to examine the physical compatibility of ceftolozane-tazobactam with common i.v. medications during simulated Y-site administration are presented. METHODS: Ceftolozane-tazobactam was reconstituted according to manufacturer recommendations and diluted with 0.9% sodium chloride or 5% dextrose to solutions containing 15 mg (10 mg of ceftolozane and 5 mg of tazobactam)/mL. All other i.v. drugs were prepared according to manufacturer recommendations and diluted with 0...
January 1, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/27999024/does-moderate-renal-impairment-affect-clinical-outcomes-in-complicated-intra-abdominal-and-complicated-urinary-tract-infections-analysis-of-two-randomized-controlled-trials-with-ceftolozane-tazobactam
#4
Ravina Kullar, Florian M Wagenlehner, Myra W Popejoy, Jianmin Long, Brian Yu, Ellie J C Goldstein
OBJECTIVES: For reasons not well understood, antibacterials can yield lower cure rates in renally impaired patients. We explored this subject for the novel antibacterial ceftolozane/tazobactam. METHODS: ASPECT-complicated intra-abdominal infections (cIAIs) and ASPECT-complicated urinary tract infections (cUTIs) were randomized, double-blinded clinical trials. Analyses in moderate [creatinine clearance (CLCR) 30-50 mL/min] and mild/no (CLCR > 50 mL/min) renal impairment (RI) patients were pre-specified as exploratory endpoints in the statistical analysis plans...
December 20, 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27988068/in-vivo-pharmacodynamics-of-piperacillin-tazobactam-implications-for-antimicrobial-efficacy-and-resistance-suppression-with-innovator-and-generic-products
#5
Carlos A Rodriguez, Maria Agudelo, Andres F Zuluaga, Omar Vesga
Recent studies have shown that the pharmacodynamic (PD) index driving the efficacy of β-lactam/β-lactamase inhibitor combinations such as ceftazidime/avibactam and ceftolozane/tazobactam is the percentage of time the free inhibitor concentration is above a threshold (fT>threshold). However, data with piperacillin/tazobactam (TZP) are scarce. Here we aimed to assess the relationship between fT>threshold and TZP antibacterial efficacy by a population pharmacokinetic study in mice and dose-effect experiments in a neutropenic murine thigh infection model with two isogenic strains of Escherichia coli differentially expressing TEM-1 β-lactamase...
November 23, 2016: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/27970761/budget-impact-analysis-of-ceftolozane-tazobactam-zerbaxa-for-the-treatment-of-complicated-intra-abdominal-infections-and-complicated-urinary-tract-infections-in-the-italian-setting
#6
M Barbieri, D Crocchiolo, M A Veneziano
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27959289/newer-intravenous-antibiotics-in-the-intensive-care-unit-ceftaroline-ceftolozane-tazobactam-and-ceftazidime-avibactam
#7
Kathryn A Connor
No abstract text is available yet for this article.
October 2016: AACN Advanced Critical Care
https://www.readbyqxmd.com/read/27956431/salvage-therapy-with-ceftolozane-tazobactam-for-multidrug-resistant-pseudomonas-aeruginosa-infections
#8
Juan José Castón, Álvaro De la Torre, Isabel Ruiz-Camps, M Luisa Sorlí, Vicente Torres, Julián Torre-Cisneros
Infections caused by multidrug-resistant Pseudomonas aeruginosa (MDRPA) present a major problem for therapeutic management. We report our experience in 12 patients with severe MDRPA infections (of which 6 were pneumonias) who received salvage therapy with ceftolozane/tazobactam after inappropriate empirical treatment and/or suboptimal targeted treatment. Although 10 of the 12 patients (83.3%) had septic shock, only 3 patients (25%) died during follow-up. Microbiological cure was observed in 7 patients (58.3%)...
December 12, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27943223/in-vitro-activity-of-ceftolozane-tazobactam-alone-or-with-an-aminoglycoside-against-multi-drug-resistant-pseudomonas-aeruginosa-from-pediatric-cystic-fibrosis-patients
#9
Aimee M Dassner, Christina Sutherland, Jennifer Girotto, David P Nicolau
INTRODUCTION: Gram-negative multi-drug resistance is an emerging threat among pediatric patients with cystic fibrosis (CF). Ceftolozane/tazobactam (C/T) is an extended-spectrum cephalosporin/beta-lactamase inhibitor combination that has been shown to maintain activity against MDR P. aeruginosa isolates. The understanding of C/T effectiveness in pediatric patients is extremely limited. Minimum inhibitory concentration (MIC) testing and time-kill analyses were performed to better understand the antimicrobial susceptibility and potential role of C/T...
December 9, 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27942218/ceftolozane-tazobactam-and-ceftazidime-avibactam-for-the-treatment-of-complicated-intra-abdominal-infections
#10
REVIEW
Kellie J Goodlet, David P Nicolau, Michael D Nailor
Complicated intra-abdominal infections (cIAI) represent a large proportion of all hospital admissions and are a major cause of morbidity and mortality in the intensive care unit. Rising rates of multidrug resistant organisms (MDRO), including extended-spectrum β-lactamase producing Enterobacteriaceae and carbapenem-nonsusceptible Pseudomonas spp., for which there are few remaining active antimicrobial agents, pose an increased challenge to clinicians. Patients with frequent exposures to the health care system or multiple recurrent IAIs are at increased risk for MDRO; however, treatment options have traditionally been limited, in some cases necessitating the utilization of last-line agents with unfavorable side-effect profiles...
2016: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/27931793/in-vitro-pharmacodynamic-evaluation-of-ceftolozane-tazobactam-against-%C3%AE-lactamase-producing-escherichia-coli-in-a-hollow-fibre-infection-model
#11
Rachel L Soon, Justin R Lenhard, Zackery P Bulman, Patricia N Holden, Pamela Kelchlin, Judith N Steenbergen, Lawrence V Friedrich, Alan Forrest, Brian T Tsuji
The proliferation of multidrug-resistant Gram-negative pathogens has been exacerbated by a lack of novel agents in current development by pharmaceutical companies. Ceftolozane/tazobactam was recently approved by the FDA for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. In the present study, the activity of ceftolozane/tazobactam against four isogenic Escherichia coli strains was investigated in a hollow-fibre infection model simulating various clinical dosing regimens...
January 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/27887579/outcomes-of-high-dose-levofloxacin-therapy-remain-bound-to-the-levofloxacin-minimum-inhibitory-concentration-in-complicated-urinary-tract-infections
#12
Eliana S Armstrong, Janelle A Mikulca, Daniel J Cloutier, Caleb A Bliss, Judith N Steenbergen
BACKGROUND: Fluoroquinolones are a guideline-recommended therapy for complicated urinary tract infections, including pyelonephritis. Elevated drug concentrations of fluoroquinolones in the urine and therapy with high-dose levofloxacin are believed to overcome resistance and effectively treat infections caused by resistant bacteria. The ASPECT-cUTI phase 3 clinical trial (ClinicalTrials.gov, NCT01345929 and NCT01345955 , both registered April 28, 2011) provided an opportunity to test this hypothesis by examining the clinical and microbiological outcomes of high-dose levofloxacin treatment by levofloxacin minimum inhibitory concentration...
November 25, 2016: BMC Infectious Diseases
https://www.readbyqxmd.com/read/27850312/673-real-world-evaluation-of-ceftolozane-tazobactam-in-a-large-cohort-of-hospitals-in-the-united-states
#13
Sanjay Merchant, Elizabeth Rhee, John Hawkshead, Rishi Agarwal, Vaibhav Kapoor, Nicole Cossrow
No abstract text is available yet for this article.
December 2016: Critical Care Medicine
https://www.readbyqxmd.com/read/27850300/661-pk-pd-and-safety-of-3-g-ceftolozane-tazobactam-in-critically-ill-augmented-renal-clearance-patients
#14
Luzelena Caro, Kajal Larson, David Nicolau, Jan DeWaele, Joseph Kuti, Elaine Gadzicki, Brian Yu, Elizabeth Rhee
No abstract text is available yet for this article.
December 2016: Critical Care Medicine
https://www.readbyqxmd.com/read/27850290/651-ceftolozane-tazobactam-and-ceftazidime-avibactam-against-meropenem-resistant-pseudomonas-aeruginosa
#15
Mordechai Grupper, Christina Sutherland, David Nicolau
No abstract text is available yet for this article.
December 2016: Critical Care Medicine
https://www.readbyqxmd.com/read/27818808/persistent-bacteremia-from-pseudomonas-aeruginosa-with-in-vitro-resistance-to-the-novel-antibiotics-ceftolozane-tazobactam-and-ceftazidime-avibactam
#16
Louie Mar Gangcuangco, Patricia Clark, Cynthia Stewart, Goran Miljkovic, Zane K Saul
Ceftazidime-avibactam and ceftolozane-tazobactam are new antimicrobials with activity against multidrug-resistant Pseudomonas aeruginosa. We present the first case of persistent P. aeruginosa bacteremia with in vitro resistance to these novel antimicrobials. A 68-year-old man with newly diagnosed follicular lymphoma was admitted to the medical intensive care unit for sepsis and right lower extremity cellulitis. The patient was placed empirically on vancomycin and piperacillin-tazobactam. Blood cultures from Day 1 of hospitalization grew P...
2016: Case Reports in Infectious Diseases
https://www.readbyqxmd.com/read/27795348/comparison-of-etest-to-broth-microdilution-for-testing-of-susceptibility-of-pseudomonas-aeruginosa-to-ceftolozane-tazobactam
#17
LETTER
Lauren K Flynt, Michael P Veve, Linoj P Samuel, Robert J Tibbetts
No abstract text is available yet for this article.
January 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/27743202/updates-in-the-management-of-cephalosporin-resistant-gram-negative-bacteria
#18
REVIEW
Andre Arizpe, Kelly R Reveles, Shrina D Patel, Samuel L Aitken
Resistance to cephalosporins is now common among Gram-negative bacterial infections, including those caused by the Enterobacteriaceae and Pseudomonas aeruginosa, posing a major threat to public health. As resistance to the traditional drugs of choice for these infections, carbapenems, has also become increasingly common, interest in cefepime and piperacillin-tazobactam as carbapenem-sparing alternatives has increased. Additionally, the availability of the novel β-lactam-β-lactamase inhibitor combinations ceftolozane-tazobactam and ceftazidime-avibactam has added to the antimicrobial armamentarium available to treat these multidrug-resistant infections...
December 2016: Current Infectious Disease Reports
https://www.readbyqxmd.com/read/27712137/an-update-on-the-management-of-urinary-tract-infections-in-the-era-of-antimicrobial-resistance
#19
Mazen S Bader, Mark Loeb, Annie A Brooks
Urinary tract infections (UTIs) caused by antibiotic-resistant Gram-negative bacteria are a growing concern due to limited therapeutic options. Gram-negative bacteria, specifically Enterobacteriaceae, are common causes of both community-acquired and hospital acquired UTIs. These organisms can acquire genes that encode for multiple antibiotic resistance mechanisms, including extended-spectrum-lactamases (ESBLs), AmpC- β -lactamase, and carbapenemases. The assessment of suspected UTI includes identification of characteristic symptoms or signs, urinalysis, dipstick or microscopic tests, and urine culture if indicated...
October 7, 2016: Postgraduate Medicine
https://www.readbyqxmd.com/read/27707990/efficacy-of-ceftolozane-tazobactam-against-urinary-tract-and-intra-abdominal-infections-caused-by-esbl-producing-escherichia-coli-and-klebsiella-pneumoniae-a-pooled-analysis-of-phase-3-clinical-trials
#20
Myra W Popejoy, David L Paterson, Daniel Cloutier, Jennifer A Huntington, Benjamin Miller, Caleb A Bliss, Judith N Steenbergen, Ellie Hershberger, Obiamiwe Umeh, Keith S Kaye
OBJECTIVES: The increase in infections caused by drug-resistant ESBL-producing Enterobacteriaceae (ESBL-ENT) is a global concern. The characteristics and outcomes of patients infected with ESBL-ENT were examined in a pooled analysis of Phase 3 clinical trials of ceftolozane/tazobactam in patients with complicated urinary tract infections (ASPECT-cUTI) and complicated intra-abdominal infections (ASPECT-cIAI). METHODS: Trials were randomized and double blind. The ASPECT-cUTI regimen was 7 days of either intravenous ceftolozane/tazobactam (1...
January 2017: Journal of Antimicrobial Chemotherapy
keyword
keyword
118181
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"